3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
6
sargramostim
5
Psychiatric Rehabilitation
5
Early Intervention, Educational
5
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
palbociclib
3
Trastuzumab
3
Therapeutics
3
Standard of Care
3
Radiotherapy
3
Oxaliplatin
3
Methods
3
Irinotecan
3
Interferon-alpha
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Docetaxel
3
Bortezomib
3
temsirolimus
2
motexafin gadolinium
2
entinostat
2
cemiplimab
2
cediranib
2
Specimen Handling
2
Radiosurgery
2
Practice Guidelines as Topic
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
bexmarilimab
×
Genitourinary
×
Clear all
NCT05104905
2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2
Withdrawn